13F reference period
Q3 2026
Security Snapshot
CytoMed Therapeutics Ltd - Ordinary Shares, no par value per share (GDTC) Institutional Ownership
CUSIP: Y1R80M106
13F Institutional Holders and Ownership History from Q2 2023 to Q3 2026
Institutions Reporting
1
Shares (Excl. Options)
26.97K
Full value: 26,965 · shares · 30 Sep 2026Price
$0.91
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, no par value per share
- Symbol
- GDTC on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 26,965
- Total 13F value
- $24,447
- Portfolio coverage rank
- 0%
- Share change
- +19,933
- Value change
- +$17,204
- Number of holders
- 1
- Shares outstanding
- 11,934,325
- SEC-reported price per share
- $0.91
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- GDTC - CytoMed Therapeutics Ltd - Ordinary Shares, no par value per share is tracked under CUSIP Y1R80M106.
- 1 institution reported positions in Q3 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 3 to 1 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$12.24K
Full value: $12,240 · USD · 30 Jun 2026.$24.45K
Full value: $24,447 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q3 2026.
Security key
Y1R80M106
13F reference period
Q3 2026
13F holders
1
13D/G owners
3
CIK / CUSIP context first
Open Q3 2026 holders
GDTC full holder history
CytoMed Therapeutics Ltd SEC filings
CytoMed Therapeutics Ltd company facts
CytoMed Therapeutics Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP Y1R80M106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
GDTC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Choo Chee Kong | 25% | +1% | $2,853,796 | +$27,788 | 3,003,996 | +0.98% | Choo Chee Kong | 12 Oct 2026 |
| mDR Ltd | 10% | -12% | $1,131,947 | -$110,590 | 1,191,523 | -8.9% | mDR LTD | 12 Oct 2026 |
| 28 Consultants Ltd | 7.6% | $2,095,145 | 880,313 | 28 Consultants Ltd | 17 Feb 2025 |
As of 30 Sep 2026,
1
institutional investors reported holding
shares of
CytoMed Therapeutics Ltd - Ordinary Shares, no par value per share (GDTC).
This represents
0.23%
of the company’s total
outstanding shares.
26.97K
Full value: 26,965 · shares · 30 Sep 202611.93M
Full value: 11,934,325 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Headline period
Q3 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 26,965 | $24,447 | +$17,204 | $0.91 | 1 |
| 2026 Q2 | 11,884 | $12,240 | -$4,285 | $1.03 | 3 |
| 2026 Q1 | 16,339 | $16,339 | -$54,074 | $1.00 | 3 |
| 2025 Q4 | 53,128 | $70,777 | +$43,411 | $1.34 | 5 |
| 2025 Q3 | 18,124 | $36,067 | -$57,854 | $1.99 | 2 |
| 2025 Q2 | 45,250 | $98,493 | +$29,244 | $2.19 | 2 |
| 2025 Q1 | 31,697 | $70,308 | +$48,294 | $2.22 | 2 |
| 2024 Q4 | 10,098 | $34,333 | +$34,126 | $3.40 | 1 |
| 2024 Q3 | 61 | $96 | +$96 | $1.57 | 1 |
| 2024 Q2 | 0 | $0 | -$28 | $0.91 | 0 |
| 2024 Q1 | 13 | $28 | -$19,022 | $2.15 | 1 |
| 2023 Q4 | 4,382 | $21,472 | +$135 | $4.90 | 2 |
| 2023 Q3 | 5,884 | $20,670 | +$20,481 | $3.51 | 2 |
| 2023 Q2 | 54 | $165 | +$165 | $3.06 | 1 |